Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cyteir Therapeutics Inc (NQ: CYT ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open - Bid (Size) 3.070 (100) Ask (Size) 3.140 (105) Prev. Close 3.020 Today's Range N/A - N/A 52wk Range 2.790 - 3.190 Shares Outstanding 71,281,616 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq March 07, 2024 From Cyteir Therapeutics Via Business Wire Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile October 12, 2023 From Cyteir Therapeutics Via Business Wire Performance More News Read More Nasdaq Jumps 200 Points; Baudax Bio Shares Spike Higher June 30, 2023 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session June 30, 2023 Via Benzinga Cyteir Therapeutics (NASDAQ: CYT) to Dissolve After Discontinuing Development of CYT-0851 June 30, 2023 Via Spotlight Growth Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session June 30, 2023 Via Benzinga Crude Oil Rises Over 1%; Fed's Preferred Inflation Gauge Slows In May June 30, 2023 Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session June 30, 2023 Via Benzinga Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution June 30, 2023 From Cyteir Therapeutics Via Business Wire Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile June 03, 2023 From Cyteir Therapeutics Via Business Wire Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights May 10, 2023 From Cyteir Therapeutics, Inc. Via Business Wire Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights March 23, 2023 From Cyteir Therapeutics Via Business Wire Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer February 06, 2023 From Cyteir Therapeutics Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023 February 03, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023 January 30, 2023 Via Benzinga Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway January 19, 2023 From Cyteir Therapeutics Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023 January 20, 2023 Via Benzinga Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights November 07, 2022 From Cyteir Therapeutics Via Business Wire Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium October 12, 2022 From Cyteir Therapeutics Via Business Wire 5 Value Stocks In The Healthcare Sector September 12, 2022 Via Benzinga Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference August 31, 2022 From Cyteir Therapeutics Via Business Wire Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights August 08, 2022 From Cyteir Therapeutics Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 September 09, 2022 Via Benzinga Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference August 01, 2022 From Cyteir Therapeutics Via Business Wire Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday July 27, 2022 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.